This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Monograph of Salbutamol Pressurized Inhalation from BP
2010
Salbutamol Pressurized Inhalation
Action and useBeta2-adrenoceptor agonist; bronchodilator.
Definition Salbutamol Pressurized Inhalation is a suspension of either Salbutamol or Salbutamol Sulphate in a suitable liquid in a suitable pressurized container. The pressurized inhalation complies with the requirements stated under Preparations for Inhalation and with the following requirements.
Content of salbutamol, C13H21NO3
80.0 to 120.0% of the amount stated to be delivered by actuation of the valve.
Identification
A. The infrared absorption spectrum, Appendix II A, in the range 1650 to 400 cm-1 is concordant with the reference spectrum of either salbutamol (RS 314) or salbutamol sulphate (RS 315), as appropriate. Examine the substance as dispersion in potassium bromide prepared in the following manner. Discharge the inhaler a sufficient number of times into a mortar to obtain 2 mg of Salbutamol, grind the residue thoroughly with 0.1 g of potassium bromide, add a further 0.2 g of potassium bromide and mix thoroughly.
B. In the test for related substances, the principal peak in the chromatogram obtained with solution (2) corresponds
to the peak due to salbutamol in the chromatogram obtained with solution (3).
Tests
Related substances
Carry out the method for liquid chromatography, Appendix III D, using the following solutions.
For pressurized inhalations containing Salbutamol use the following solution as solution (1). Discharge the inhaler a sufficient number of times into a small, dry beaker to obtain 5 mg of Salbutamol and dissolve the residue in 10 ml of the mobile phase; mix with the aid of ultrasound until the solution is clear.
For pressurized inhalations containing Salbutamol Sulphate use the following solution as solution (1). Discharge the inhaler a sufficient number of times into a small, dry beaker to obtain the equivalent of 5 mg of salbutamol and dissolve the residue in 10 ml of the mobile phase; mix with the aid of ultrasound until the solution is clear.
For solution (2) dilute 1 volume of solution (1) to 100 volumes with the mobile phase. Solution (3) contains 0.0004% w/v of salbutamol impurity B EPCRS and 0.0005% w/v of salbutamol sulphate EPCRS in the mobile phase. For solution (1) allow the chromatography to proceed for 25 times the retention time of salbutamol (retention time of salbutamol, about 1.9 minutes).
The chromatographic procedure may be carried out using (a) a stainless steel column (15 cm × 3.9 mm) packed with spherical end-capped octylsilyl silica gel for
chromatography (5 µm) with a specific surface area of 335 m2 per g, a pore size of 10 nm and a carbon loading of 11.7% (Waters Symmetry C8 is suitable), (b) as the mobile phase with a flow rate of 1 ml per minute a mixture of 22 volumes of acetonitrile and 78 volumes of a solution containing 0.287% w/v of sodium heptanesulphonate and 0.25% w/v of potassium dihydrogen orthophosphate adjusted to pH 3.65 with 2M orthophosphoric acid and (c) a detection wavelength of 220 nm.
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution factor between the two principal peaks is at least 3.0.
In the chromatogram obtained with solution (1) the area of any secondary peak is not greater than half the area of the principal peak in the chromatogram obtained with solution (2) (0.5%) and the sum of the areas of any such peaks is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (1%).
Salbutamol ketone
Carry out the method for liquid chromatography, Appendix III D, using the following solutions. For solution (1) dilute a quantity of solution (1) prepared above in the test for related substances, with sufficient water to produce a solution containing the equivalent of 0.050% w/v of salbutamol. Solution (2) contains 0.00025% w/v of salbutamol ketone impurity BPCRS in water.
The chromatographic procedure may be carried out using (a) a stainless steel column (25 cm × 4.6 mm) packed with end-capped octylsilyl silica gel for chromatography (5 µm)
(Hypersil BDS C8 is suitable) maintained at 30°, (b) as the mobile phase with a flow rate of 1 ml per minute the changing proportions of mobile phases A and B described below and (c) a detection wavelength of 276 nm.
Mobile phase A a mixture of 1.5 volumes of propan-2-ol and 98.5 volumes of 0.1m ammonium acetate adjusted to pH 4.5 with glacial acetic acid.
Mobile phase B propan-2-ol.
In the chromatogram obtained with solution (1) the area of any peak corresponding to salbutamol ketone is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.5%).
Deposition of the emitted dose
Carry out the test for aerodynamic assessment of fine particles, Appendix XII C7, using Apparatus A but determining the content of active ingredient as described below.
For pressurized inhalations containing Salbutamol use 7 ml of methanol in the upper impingement chamber and 30 ml of methanol in the lower impingement chamber. Use methanol to wash the coupling tube, E, and transfer the combined solution and washings in the lower impingement chamber to a 100 ml graduated flask containing 22.5 ml of a 0.1% w/v solution of ammonium acetate, rinsing the
chamber with methanol, and dilute the combined solution and washings to 100 ml with methanol.
For pressurized inhalations containing Salbutamol Sulphate use 7 ml of water in the upper impingement chamber and 30 ml of water in the lower impingement chamber. Use a mixture of equal volumes of methanol and water to wash the coupling tube, E, and transfer the combined solution and washings in the lower impingement chamber to a 100 ml graduated flask containing 22.5 ml of a 0.1% w/v solution of ammonium acetate, rinsing the chamber with a mixture of equal volumes of methanol and water, and dilute the combined solution and washings to 100 ml with water.
Carry out the method for liquid chromatography, Appendix III D, using the following solutions. Solution (1) contains 0.0006% w/v of 2-tert-butylamino-1-(4-hydroxy-3-methylphenyl) ethanol sulphate BPCRS and 0.0005% w/v of salbutamol BPCRS in the mobile phase. Solution (2) is a 0.0005% w/v solution of salbutamol BPCRS in the mobile phase. For solution (3) use the diluted solution from the lower impingement chamber.
The chromatographic procedure may be carried out using (a) a stainless steel column (10 cm × 5 mm) packed with octadecylsilyl silica gel for chromatography (5 µm) (Spherisorb ODS 1 is suitable), (b) a mixture of 225 volumes of a 0.1% w/v solution of ammonium acetate and 800 volumes of methanol as the mobile phase with a flow rate of 2 ml per minute and (c) a detection wavelength of 276 nm.
The test is not valid unless the resolution factor between the two principal peaks in the chromatogram obtained with
Calculate the amount of salbutamol, C13H21NO3, delivered to the lower impingement chamber per actuation of the valve using the declared content of C13H21NO3 in salbutamol BPCRS. Not less than 35% of the average amount of salbutamol delivered per actuation of the valve, calculated as the average of the three results determined in the Assay, is deposited in the lower impingement chamber.
Assay
Determine the content of active ingredient delivered by the first 10 successive combined actuations of the valve after priming.
For pressurized inhalations containing Salbutamol carry out the procedure for Content of active ingredient delivered by actuation of the valve described under Pressurized Inhalations, beginning at the words 'Remove the pressurized container from the actuator…' and ending at the words '… to the volume specified in the monograph', using 35 ml of methanol in the vessel. Add 22.5 ml of a 0.1% w/v solution of ammonium acetate to the combined solution and washings obtained from the set of 10 combined actuations and dilute to 100 ml with methanol (solution A).
For pressurized inhalations containing Salbutamol Sulphate carry out the procedure for Content of active ingredient delivered by actuation of the valve described under Pressurized Inhalations, beginning at the words 'Remove the pressurized container from the actuator…' and ending at the words '… to the volume specified in the monograph', using 35 ml of a mixture of equal volumes of methanol and water
in the vessel. Add 22.5 ml of a 0.1% w/v solution of ammonium
acetate to the combined solution and washings obtained from the set of 10 combined actuations and dilute to 100 ml with water (solution A).
Determine the amount of active ingredient in the 10 combined actuations using the following method of analysis. Carry out the method for liquid chromatography, Appendix III D, using the following solutions. Solution (1) contains 0.0012% w/v of 2-tert-butylamino-1-(4-hydroxy-3-methylphenyl) ethanol sulphate BPCRS and 0.001% w/v of salbutamol BPCRS in the mobile phase. Solution (2) contains 0.001% w/v of salbutamol BPCRS in the mobile phase. For solution (3) use solution A.
The chromatographic conditions described under Deposition of the emitted dose may be used.
The test is not valid unless the resolution factor between the two principal peaks in the chromatogram obtained with solution (1) is at least 1.5.
Calculate the average content of C13H21NO3 delivered by a single actuation of the valve using the declared content of C13H21NO3 in salbutamol BPCRS.
Determine the content of active ingredient a second and a third time by repeating the procedure on the middle 10 and on the last 10 successive combined actuations of the valve, as estimated from the number of deliveries available from the container as stated on the label. For each of the three determinations the average content of C13H21NO3 delivered by a single actuation of the valve is within the limits stated under Content of salbutamol.
The label on the container states (1) whether the preparation contains Salbutamol or Salbutamol Sulphate; (2) where applicable, that the preparation does not contain chlorofluorocarbon propellants (CFCs).
When the active ingredient is Salbutamol Sulphate, the quantity is stated in terms of the equivalent amount of salbutamol
Sampling apparatus for pressurized metered-dose inhalers
Reference: United States of Pharmacopeia 32/National Formulary 27, 2009.